医药新闻
- (2021-12-11)
- (2021-12-10)
- (2021-12-10)
- (2021-12-10)
- (2021-12-10)
- (2021-12-10)
- (2021-12-10)
- (2021-12-09)
- (2021-12-09)
- (2021-12-09)
- (2021-12-09)
- (2021-12-09)
- (2021-12-09)
- (2021-12-09)
- (2021-12-09)
- (2021-12-08)
- (2021-12-08)
- (2021-12-08)
- (2021-12-08)
- (2021-12-08)
- (2021-12-08)
- (2021-12-08)
- (2021-12-08)
- (2021-12-08)
DIAN-TU在以TAU为靶点治疗显性遗传阿尔茨海默病的临床试验中选择LECANEMAB作为基础抗淀粉样蛋白,评估探索性治疗效果
(2021-12-08)- (2021-12-07)
- (2021-12-07)
- (2021-12-07)
- (2021-12-07)
- (2021-12-07)
- (2021-12-07)
- (2021-12-07)
- (2021-12-07)
- (2021-12-07)
- (2021-12-06)
- (2021-12-06)
- (2021-12-06)
- (2021-12-06)
- (2021-12-06)
- (2021-12-06)
- (2021-12-06)
- (2021-12-06)
- (2021-12-06)
- (2021-12-06)
- (2021-12-06)
- (2021-12-03)
- (2021-12-03)
- (2021-12-03)
- (2021-12-03)
- (2021-12-03)
- (2021-12-03)
- (2021-12-02)
- (2021-12-02)
- (2021-12-02)
- (2021-12-02)
- (2021-12-01)
- (2021-12-01)
- (2021-12-01)
- (2021-12-01)
- (2021-12-01)